TitusBen ☆ 2024-10-17 07:40 (204 d 20:54 ago) Posting: # 24235 Views: 2,528 |
|
Hello all, This is my 1st post here and excited to learn/share science. I just want to share and ask your suggestions. My study - I am carrying out Virtual BE studies for a SR-formulations and comparing its PK endpoints (Cmax, AUC). Doubt - I am confused or doubting my manually chose PK sampling time points. Drug X - Tmax - 8.40hr Therefore, I chose 12 time points (aligns with US regulatory guideline) - 1, 3, 5, 6, 7, 7.5, 8, 8.5, 9, 10, 16, and 24 hrs which covers that absorption, distribution and elimination phase of the compound. Any suggestions here to capture the PK profile the drug much better? Thanks, Titus |
Helmut ★★★ ![]() ![]() Vienna, Austria, 2024-10-17 12:56 (204 d 15:39 ago) @ TitusBen Posting: # 24236 Views: 2,059 |
|
Hi Titus! ❝ This is my 1st post here and excited to learn/share science. ❝ My study - I am carrying out Virtual BE studies for a SR-formulations and comparing its PK endpoints (Cmax, AUC). ❝ Doubt - I am confused or doubting my manually chose PK sampling time points. ❝ Drug X - Tmax - 8.40hr ❝ Therefore, I chose 12 time points (aligns with US regulatory guideline) - 1, 3, 5, 6, 7, 7.5, 8, 8.5, 9, 10, 16, and 24 hrs which covers that absorption, distribution and elimination phase of the compound. ❝ Any suggestions here to capture the PK profile the drug much better? Do you know more about the drug than its tmax? Further, tmax = 8.4 h is not set in stone. Profiles of SR formulations are sometimes pretty flat. Cmax is a composite PK metric (depends not only on \(\small{k_\text{a}}\) but also on \(\small{k_\text{e}}\) and \(\small{f}\)) and therefore, a poor predictor of \(\small{k_\text{a}}\). Since \(\small{k_\text{a}}\) varies between subjects, I would add more sampling time points around the anticipated tmax. — Dif-tor heh smusma 🖖🏼 Довге життя Україна! ![]() Helmut Schütz ![]() The quality of responses received is directly proportional to the quality of the question asked. 🚮 Science Quotes |
TitusBen ☆ 2024-10-18 08:24 (203 d 20:11 ago) @ Helmut Posting: # 24237 Views: 1,967 |
|
Dear Helmut! ❝ ❝ This is my 1st post here and excited to learn/share science. ❝ Welcome to the club. ❝ Do you know more about the drug than its tmax? Further, tmax = 8.4 h is not set in stone. Profiles of SR formulations are sometimes pretty flat. Cmax is a composite PK metric (depends not only on \(\small{k_\text{a}}\) but also on \(\small{k_\text{e}}\) and \(\small{f}\)) and therefore, a poor predictor of \(\small{k_\text{a}}\). Since \(\small{k_\text{a}}\) varies between subjects, I would add more sampling time points around the anticipated tmax. About the Drug - Since the study is a simulation-based experiment, I developed a hypothetical drug which is expected to have more colonic absorption to support my theoretical objective. I have pasted the Log-Conc profile of the drug for your reference below. ![]() In my case, I do not see flip-flop kinetics, therefore I will assume the Tmax = 8.4 h as reliable parameter and add further more (3-5) time points. I also would like to know, what are the criteria to choose the PK sampling time points as best as possible to capture the PK estimates well? (All I know to describe the ADE phase and at least three or more terminal elimination half-lives of the drug). Kindly correct me if I am wrong in my assumptions. Thanks a lot and open for comments! Best Regards, Titus |
Helmut ★★★ ![]() ![]() Vienna, Austria, 2024-10-18 11:16 (203 d 17:19 ago) @ TitusBen Posting: # 24238 Views: 1,957 |
|
Hi Titus, ❝ ❝ Do you know more about the drug than its tmax? ❝ About the Drug - Since the study is a simulation-based experiment, I developed a hypothetical drug which is expected to have more colonic absorption to support my theoretical objective. ❝ I have pasted the Log-Conc profile of the drug for your reference below. For an example see the profile of mesalazine (scroll down to Fig. 5 because what’s given in the NDA is crap). ❝ I totally agree with you point regarding Cmax. But also I want to be realistic in PK sampling time points to clinical setting. I mean, no over-sampling. therefore, according to US FDA guidance "Bioequivalence Studies With Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA Guidance for Industry, 2021", I can go upto 18 time points. ![]() However, they try to cover most of the ‘common’ cases, which might not be yours. For my approach see this presentation (slides 7–9). Unfortunately, lag-times in LALAs are terribly variable and you have to take that into account (in my simulations I use a truncated normal distribution and discretize it for the sampling times). See the Not a LALA but a PPI with extremely variable lag-times. Due to the acid-sensitivity of PPIs, all formulations are gastric resistant coated. Here the variability is caused by physiology (gastric motility / emptying) and is not a property of the formulation. Do you see how difficult it is to ‘catch’ Cmax? ❝ In my case, I do not see flip-flop kinetics, therefore I will assume the Tmax = 8.4 h as reliable parameter and add further more (3-5) time points. ❝ I also would like to know, what are the criteria to choose the PK sampling time points as best as possible to capture the PK estimates well? (All I know to describe the ADE phase and at least three or more terminal elimination half-lives of the drug).
— Dif-tor heh smusma 🖖🏼 Довге життя Україна! ![]() Helmut Schütz ![]() The quality of responses received is directly proportional to the quality of the question asked. 🚮 Science Quotes |
TitusBen ☆ 2024-10-18 18:45 (203 d 09:49 ago) @ Helmut Posting: # 24241 Views: 1,890 |
|
Dear Helmut, Thanks for your kind response and the clarification. I appreciate it. It helped me to focus more! ❝ In your original post you talked about an SR formulation. Locally applied, locally acting drugs (LALAs) are delayed release (DR). The correct model is simple (one or two compartments but with a substantial lag-time), which is not your current one. Yes, I agree. Since the drug has major fraction absorbed in colon, I assumed it to be a SR formulation. But clearly in the plot, there is no significant lag time. I believe, lag-time can be only observed in normal Conc-time plot. Isn't? Thanks, Titus |
Helmut ★★★ ![]() ![]() Vienna, Austria, 2024-10-19 10:20 (202 d 18:15 ago) @ TitusBen Posting: # 24242 Views: 1,849 |
|
Hi Titus, ❝ But clearly in the plot, there is no significant lag time. ❝ I believe, lag-time can be only observed in normal Conc-time plot. Isn't? By convention in NCA BQLs before tmax are set to zero. Of course, 0 cannot be shown in a log-linear plot. By another convention, tlag is defined as the time point before the first measurable concentration. Obviously that’s not correct (see also there). The true one is a little later. Another approach1 is not implemented in any software; roll out your own code. Of course, you can estimate tlag by a PK model.2
— Dif-tor heh smusma 🖖🏼 Довге життя Україна! ![]() Helmut Schütz ![]() The quality of responses received is directly proportional to the quality of the question asked. 🚮 Science Quotes |